The largest community of pharma leaders

Former Surgeon General of the U.S. Navy, Vice Admiral Matthew L. Nathan, M.D., Joins Board of Directors at Minneapolis-based Humanetics

MINNEAPOLIS–()–Humanetics Corporation (Humanetics) has elected Vice Admiral Matthew L. Nathan, M.D. (ret. 2016) to its Board of Directors. Dr. Nathan has held a seat on the Company’s Medical Advisory board since 2017.

Dr. Nathan served as the 37th Surgeon General of the Navy and Chief of the Navy’s Bureau of Medicine and Surgery, where he oversaw 64,000 personnel with a budget approaching $9 billion. Dr. Nathan also served as Commander, Walter Reed National Military Medical Center and Navy Medicine, where he managed the largest medical integration and construction project in the Department of Defense history. He most recently served as Senior Vice President Physician Practices and Enterprise Leader for the campus at the WakeMed Health System in Raleigh, North Carolina and is now serving as a fellow at Harvard University, Cambridge, Massachusetts. He also served on the Board of Regents for both the National Library of Medicine and the Uniformed Services University of the Health Sciences. Dr. Nathan is board certified and holds fellow status in the American College of Physicians and the American College of Healthcare Executives. 

Humanetics is developing BIO 300, a proprietary new drug to protect against harm caused by exposure to ionizing radiation as well as inflammatory diseases including COVID-19. BIO 300 was licensed to Humanetics by the U.S. Department of Defense, where its radioprotective and anti-inflammatory properties were initially discovered. Humanetics is also developing BIO 300 for use in cancer patients that receive radiation therapy as part of their treatment. BIO 300 is currently being studied in multiple clinical trials, both for COVID-19 patients and with patients receiving radiation therapy for non-small cell lung cancer.

“We are delighted to have Dr. Nathan join our Board of Directors,” said Ronald Zenk, CEO of Humanetics. “His extensive medical expertise and training will be invaluable to our product development and commercialization efforts; plus he possesses a unique understanding of military medicine and the needs of warfighters.”

About Humanetics Corporation

Humanetics is a clinical-stage pharmaceutical company engaged in the discovery, development and commercialization of proprietary drugs to prevent severe tissue damage caused by exposure to radiation, viral infection and other inflammatory diseases. For more information, visit www.humaneticscorp.com

Source

0FansLike
0FollowersFollow
0FollowersFollow
0FollowersFollow

Recent Articles

bioAffinity Technologies Announces Dr. Martin Tammemägi to Chair Scientific and Medical Advisory Board

SAN ANTONIO--(BUSINESS WIRE)-- #CyPathLung--bioAffinity Technologies, a privately held biotech company, today...

Evaluate Ltd. Launches Evaluate Omnium, Transforming Pharma’s Approach to Quantifying the Risk and Return of Novel Drugs

LONDON & BOSTON & TOKYO--(BUSINESS WIRE)-- #biopharma--Evaluate Ltd., the leading provider...

HCPLive® and the American Lung Association Unveil Exclusive Interview with Anthony S. Fauci, M.D.

CRANBURY, N.J.--(BUSINESS WIRE)-- #AnthonyFauci--Dr. Anthony Fauci joined Lungcast, the @MDMagazine and...

MedinCell Initiates the First Clinical Trial of Its Covid-19 Prevention Program

MONTPELLIER, France--(BUSINESS WIRE)--MedinCell (Paris:MEDCL): Access the complete press release About MedinCell...

CStone, Pfizer Enter into Strategic Collaboration to Address Oncological Needs in China

SUZHOU, China--(BUSINESS WIRE)--CStone Pharmaceuticals (“CStone”, HKEX: 2616)] and Pfizer Investment Co....
2020 Call for Writers

Are you looking to inspire others in the pharma industry through your writing? You’re invited to submit your articles to become a Featured Writer for The Pharmaceutical Marketing Group website.